PubRank

M A Koopmanschap

Author PubWeight™ 36.02‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Demographic and epidemiological determinants of healthcare costs in Netherlands: cost of illness study. BMJ 1998 2.80
2 Productivity costs measurement through quality of life? A response to the recommendation of the Washington Panel. Health Econ 1997 2.71
3 Labor and health status in economic evaluation of health care. The Health and Labor Questionnaire. Int J Technol Assess Health Care 1996 1.95
4 Productivity losses without absence: measurement validation and empirical evidence. Health Policy 1999 1.74
5 Cost-utility of exercise therapy in adolescents and young adults suffering from the patellofemoral pain syndrome. Scand J Med Sci Sports 2009 1.43
6 [Detailed analysis of the societal costs of diabetes mellitus]. Ned Tijdschr Geneeskd 2000 1.39
7 Health problems lead to considerable productivity loss at work among workers with high physical load jobs. J Clin Epidemiol 2005 1.34
8 The cost-effectiveness of drug regulation: the example of thorough QT/QTc studies. Clin Pharmacol Ther 2011 1.32
9 On the economic foundations of CEA. Ladies and gentlemen, take your positions! J Health Econ 2000 1.22
10 Diagnostic and treatment procedures induced by cervical cancer screening. Eur J Cancer 1990 1.20
11 Productivity costs in cost-effectiveness analysis: numerator or denominator: a further discussion. Health Econ 1997 1.12
12 Burden of informal caregiving for stroke patients. Identification of caregivers at risk of adverse health effects. Cerebrovasc Dis 2004 1.07
13 Productivity costs before and after absence from work: as important as common? Health Policy 2002 1.05
14 Assessment of post-stroke quality of life in cost-effectiveness studies: the usefulness of the Barthel Index and the EuroQoL-5D. Qual Life Res 2004 1.03
15 Resource consumption and costs in Dutch patients with type 2 diabetes mellitus. Results from 29 general practices. Diabet Med 2002 1.00
16 The valuation of informal care in economic appraisal. A consideration of individual choice and societal costs of time. Int J Technol Assess Health Care 1999 0.96
17 Medical consumption and costs during a one-year follow-up of patients with LUTS suggestive of BPH in six european countries: report of the TRIUMPH study. Eur Urol 2005 0.95
18 Societal perspective on the burden of migraine in The Netherlands. Pharmacoeconomics 1995 0.94
19 What really matters: an inquiry into the relative importance of dimensions of informal caregiver burden. Clin Rehabil 2004 0.94
20 Technology assessment of the Dutch Lung Transplantation Program. Int J Technol Assess Health Care 1998 0.94
21 Cost-effectiveness of integrated stroke services. QJM 2005 0.92
22 Patient and informal caregiver time in cost-effectiveness analysis. A response to the recommendations of the Washington Panel. Int J Technol Assess Health Care 1998 0.85
23 Indirect costs of disease; an international comparison. Health Policy 1995 0.83
24 Cost-effectiveness of lung transplantation in The Netherlands: a scenario analysis. Chest 1998 0.83
25 Preventive Pap-smears: balancing costs, risks and benefits. Br J Cancer 1992 0.82
26 How to calculate indirect costs in economic evaluations. Pharmacoeconomics 1998 0.82
27 The cost-effectiveness of periodic safety update reports for biologicals in Europe. Clin Pharmacol Ther 2013 0.82
28 Care and costs for advanced cervical cancer. Eur J Cancer 1992 0.81
29 Lifetime costs of lung transplantation: estimation of incremental costs. Health Econ 1997 0.80
30 The management of cervical intra-epithelial neoplasia (CIN): extensiveness and costs in The Netherlands. Eur J Cancer 1995 0.77
31 Cost-effectiveness of two endovascular treatment strategies vs intravenous thrombolysis. Acta Neurol Scand 2012 0.76
32 [The cost of illness]. Ned Tijdschr Geneeskd 1992 0.75
33 [The evaluation of the lung transplantation program at Groningen: survival rate, quality of life, and cost-effectiveness]. Ned Tijdschr Geneeskd 1998 0.75
34 [The cost of sickness in the Netherlands in 1994; the main determinants were advanced age and disabling conditions]. Ned Tijdschr Geneeskd 1998 0.75
35 [Costs of intensive care in The Netherlands]. Ned Tijdschr Geneeskd 1994 0.75